2 Information about olaparib

Marketing authorisation indication

2.1 Olaparib (Lynparza, Astra Zeneca) plus bevacizumab (Avastin, Roche) is indicated for 'the maintenance treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability'.


2.3 The list price for olaparib tablets is £2,317.50 for 56 × 150 mg tablets (excluding VAT; BNF online accessed September 2020).

The company has a commercial arrangement for olaparib tablets. The commercial arrangement additionally forms part of the managed access agreement for use of olaparib tablets in the Cancer Drugs Fund. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)